Our study suggests that conclusions from previous studies of atherosclerosis utilizing p16 or ABT-263 should be reassessed, while preclinical testing of current and novel senolytics requires the development of sensitive and lineage-specific markers of cell senescence in atherosclerosis before ascribing effects entirely to senolysis. This evidence concerns the gene CDKN2A and atherosclerosis.